TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03143816
Drug: Technosphere insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
Study: NCT04405336
Drug: tab block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of tab block to women who are doing cs
Study: NCT04405336
Drug: PCA
Normalized name: PCA
DrugBank: Pidolic acid (DB03088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: giving women PCA
Study: NCT00000320
Drug: Buprenorphine formulation: liquid vs. tablet
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: random assignment to liquid buprenorphine or tablet buprenorphine
Study: NCT04411615
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rTG form Omega-3
Study: NCT01892332
Drug: epidural block with lidocaine and fentanyl
Normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%.
Study: NCT02644018
Drug: Imidazolyl ethanamide pentandioic acid
Normalized name: IMIDAZOLYL ETHANAMIDE PENTANDIOIC ACID
DrugBank: Ingavirin (DB11944)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00910234
Drug: recombinant human erythropoietin (rhEpo)
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Study: NCT00910234
Drug: recombinant human erythropoietin (rhEpo)
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
Study: NCT00349336
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5mg/kg iv on day 1 of each 3 week cycle
Study: NCT00349336
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg/kg iv on day 1 of each 2 week cycle
Study: NCT00003336
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
Study: NCT02350361
Drug: Recombinant human endostatin
Normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human endostatin 7.5mg/m2
Study: NCT04569279
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban (Rovaltro®) is a novel oral anticoagulant that acts selectively, reversibly, and potently on activated Factor X (Factor Xa) inhibiting a critical point on the coagulation cascade. Rivaroxaban has excellent bioavailability, rapid onset of peak anticoagulation effect, and predictable pharmacokinetic and pharmacodynamic properties making routine laboratory monitoring and dose adjustments almost unnecessary (11). Rivaroxaban is an extensively studied drug and has received approvals for anticoagulation in several preventive and therapeutic indications (11). Now medical literature has some solid evidence that Rivaroxaban is comparable with other anticoagulants in terms of efficacy. Several studies imply that Rivaroxaban may have a lower risk of major bleeding (11). Several reports and small case-series (12,13) suggest that rivaroxaban may be beneficial as Warfarin in the treatment of cerebral venous thrombosis (CVT) with less or no major complications.
Study: NCT03513588
Drug: PF-06865571
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, 50 mg, 14 days, every 12 hours
Study: NCT03513588
Drug: PF-06865571
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, 300 mg, 14 days, every 12 hours
Study: NCT04569279
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (Orfarin®) is the most popular vitamin K antagonist and is considered the standard of care in many venous and arterial anticoagulation indications with extensive clinical experience regarding its use. This inexpensive and effective drug has a narrow therapeutic window that is affected by diet changing and many drug interactions, making frequent monitoring with prothrombin time (PT)/international normalized ratio (INR) highly important.(14)
Study: NCT01784380
Drug: Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04388774
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 40-minute intravenous infusion
Study: NCT02736305
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once a day for 21 days in a 28 days cycle
Study: NCT02957864
Drug: tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02957864
Drug: abacavir
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02483182
Drug: Acyclovir cream 5%
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00723320
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 10mg/d
Study: NCT00419068
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01253915
Drug: Nasal Carbon Dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 sec/nostril up to 4 times to treat one migraine
Study: NCT04636086
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation
Study: NCT02117115
Drug: Ioversol
Normalized name: Ioversol
DrugBank: Ioversol (DB09134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
Study: NCT01027871
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
Study: NCT02109679
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: multiple doses metformin given as tablet
Study: NCT02109679
Drug: BI 187004
Normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple doses BI 187004 given as tablets
Study: NCT00343252
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 ug/day, subcutaneous, 18 months
Study: NCT00343252
Drug: risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 mg/once weekly, oral, 18 months
Study: NCT02076178
Drug: 744 Tablet
Normalized name: mineral oil 0.744 MG/MG
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to almost white oval shaped film coated 30 mg tablets for oral administration
Study: NCT03682536
Drug: Luspatercept
Normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT03682536
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT03177187
Drug: Enzalutamide 40 MG
Normalized name: enzalutamide 40 MG
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide is presented in 40mg white to off white capsules or tablets. The capsules/tablets are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules/tablets. Each carton contains 4 wallets (112 soft capsules/tablets). Or tablets in bottles (120 per bottle).
Study: NCT02076178
Drug: 744 LA Injection
Normalized name: LA
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection
Study: NCT00731120
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Encapsulated vortioxetine immediate-release tablets
Study: NCT00096720
Drug: Mirapex (pramipexole)
Normalized name: pramipexole Oral Tablet [Mirapex]
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02139397
Drug: DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02139397
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01646437
Drug: Polycap
Normalized name: Atriplex polycarpa pollen
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
Study: NCT01646437
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg daily
Study: NCT01646437
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60,000 IU monthly
Study: NCT01533259
Drug: Stribild
Normalized name: Stribild
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
Study: NCT04391478
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: milrinone lactate, 1mg/ml, for intra venous use only
Study: NCT04391478
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube
Study: NCT02541760
Drug: Mometasone
Normalized name: Mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mometasone 1 puff in each side of nose for one month
Study: NCT02472769
Drug: IBP-9414
Normalized name: IBP-1118
DrugBank: IBP-1118 (DB18461)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01220284
Drug: Satraplatin in combo with vinorelbine
Normalized name: satraplatin
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)~* Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks.
Study: NCT02877537
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
Study: NCT02617849
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV every 3 weeks
Study: NCT02617849
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=6, every 3 weeks x 4
Study: NCT02617849
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m2, every 3 weeks x 4
Study: NCT01273259
Drug: DHEA Treatment
Normalized name: DHEA
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DHEA : 200 mg/day hard gelatine capsule
Study: NCT01273259
Drug: DHEA Treatment
Normalized name: DHEA
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DHEA : 25 mg/day hard gelatine capsule
Study: NCT00705354
Drug: Bacitracin
Normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
Study: NCT01762033
Drug: ASONEP
DrugBank: Sonepcizumab (DB06305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT01492465
Drug: AMG 876
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single doses of study drug administered SC, with one cohort administered IV
Study: NCT01285271
Drug: Xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
Study: NCT01285271
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
Study: NCT02434939
Drug: Low dose ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
Study: NCT02434939
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
Study: NCT03451396
Drug: Lifitegrast
Normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID
Study: NCT00315341
Drug: Buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
Study: NCT00315341
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
Study: NCT03872570
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT00690118
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg/day, 18 months
Study: NCT02926976
Drug: Risperidone with Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Study: NCT02926976
Drug: Aripiprazole with Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Study: NCT02926976
Drug: sodium valproate with Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Study: NCT03143023
Drug: fluoride toothpaste
Normalized name: sodium fluoride Toothpaste
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bactericidal toothpaste
Study: NCT00322322
Drug: L-Carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Carnitine
Study: NCT04243278
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81 mg of low dose aspirin PO for 6 months
Study: NCT00352118
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
Study: NCT00352118
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous over 1 hour on day 1.
Study: NCT00390182
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.~\*\*Radiation is the experimental part of the study.
Study: NCT00549133
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02862782
Drug: hCG (Ovitrelle 250 mcg mcg - Merck Serono)
Normalized name: ZOSTER VACCINE LIVE (OKA/MERCK)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00069238
Drug: EPOCH
Normalized name: Epoch Blemish
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
Study: NCT02097732
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
Study: NCT00276302
Drug: IPI-504
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.~For both Schedule A and B doses will be administered ≥ 72 hours apart.
Study: NCT01551212
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg
Study: NCT01551212
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule containing 0.5, 1.0, or 5.0mg
Study: NCT01767909
Drug: Insulin (Humulin® R U-100)
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
Study: NCT00108446
Drug: dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00108446
Drug: naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00108446
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04094025
Drug: dATS
Normalized name: DaTscan
DrugBank: Ioflupane I-123 (DB08824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: d-Amphetamine Transdermal System
Study: NCT01949545
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib was administered by IV injection over 30 minutes
Study: NCT02308046
Drug: Terconazole
Normalized name: Terconazole
DrugBank: Terconazole (DB00251)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01181167
Drug: edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01181167
Drug: enoxaparin sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02722733
Drug: G-CSF (filgrastim)
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes